

# Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

## VCaP

RRID:CVCL\_2235

Type: Cell Line

### Proper Citation

RRID:CVCL\_2235

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_2235](https://web.expasy.org/cellosaurus/CVCL_2235)

**Proper Citation:** RRID:CVCL\_2235

**Description:** Cell line VCaP is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Prostate carcinoma

**Defining Citation:** [PMID:11317522](#), [PMID:14518029](#), [PMID:14518030](#), [PMID:21698104](#), [PMID:22460905](#), [PMID:23447416](#), [PMID:23615946](#), [PMID:23671654](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:27397505](#), [PMID:28145883](#), [PMID:29194687](#), [PMID:30244336](#), [PMID:30305041](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:34402095](#), [PMID:35839778](#), [PMID:38892296](#)

**Comments:** Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=21698104)., Characteristics: Established from a xenograft produced by implantation of tumor cells in a SCID mouse., Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** VCaP

**Synonyms:** VCAP, Vcap, Vertebral Cancer of the Prostate

**Cross References:** BTO:BTO\_0003215, CLO:CLO\_0037117, EFO:EFO\_0007752, AddexBio:C0019001/73, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2876, BioSample:SAMN03473238, BioSample:SAMN05292448,

BioSample:SAMN10988209, cancercellines:CVCL\_2235, CCRID:3101HUMSCSP5034, CCRID:3101HUMTCHu220, Cell\_Model\_Passport:SIDM01077, ChEMBL-Cells:ChEMBL4295435, ChEMBL-Targets:ChEMBL4296508, CLS:300631, Cosmic:1028646, Cosmic:1028698, Cosmic:1043330, Cosmic:1071482, Cosmic:1689710, Cosmic:1995663, Cosmic:2580131, Cosmic-CLP:1299075, DepMap:ACH-000115, ECACC:06020201, EGA:EGAS00001000978, ENCODE:ENCBS316RCQ, ENCODE:ENCBS626UQL, GDSC:1299075, GEO:GSM525805, GEO:GSM648824, GEO:GSM887731, GEO:GSM888826, GEO:GSM1374984, GEO:GSM1440913, GEO:GSM1440914, GEO:GSM1633311, GEO:GSM1633312, GEO:GSM1633313, GEO:GSM1670571, GEO:GSM2069530, GEO:GSM2069531, GEO:GSM2069532, GEO:GSM2069533, GEO:GSM2069534, GEO:GSM2069535, GEO:GSM2069536, GEO:GSM2069537, GEO:GSM3145594, GEO:GSM3145745, GEO:GSM3407124, GEO:GSM3407125, GEO:GSM3407126, GEO:GSM3407127, GEO:GSM3407128, GEO:GSM3407129, GEO:GSM5402196, IARC\_TP53:18891, IZSLER:BS TCL 234, LiGeA:CCLE\_269, LINCS\_LDP:LCL-1147, PharmacDB:VCaP\_1653\_2019, PRIDE:PXD030304, Progenetix:CVCL\_2235, PubChem\_Cell\_line:CVCL\_2235, Wikidata:Q29511246

**ID:** CVCL\_2235

**Record Creation Time:** 20220427T221708+0000

**Record Last Update:** 20260913T010344+0000

---

## Ratings and Alerts

No rating or validation information has been found for VCaP.

No alerts have been found for VCaP.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 268 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Nayak S, et al. (2026) Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degradar and Antagonist, for the Treatment of Advanced Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 224.

Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. Molecular cancer research : MCR, 24(2), 93.

Susa T, et al. (2026) Androgen Signaling Represses Homeobox C9, an Inhibitor of Androgen Receptor, in Prostate Cancer Cells. International journal of molecular sciences,

27(4).

Li Q, et al. (2026) Phase Separation of NFIB Suppresses SLC3A2-Mediated Ferroptosis in Castration-Resistant Prostate Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(26), e15340.

Sun R, et al. (2026) KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/hnRNPA1 lactylation/AR-V7 axis. *Molecular cancer*, 25(1).

Metcalf SA, et al. (2026) Multiple ETS family transcription factors bind mutant p53 via distinct interaction regions. *FEBS letters*, 600(8), 1248.

Watterson A, et al. (2026) CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance. *Cell reports. Medicine*, 7(1), 102565.

Liu C, et al. (2026) Androgen Receptor-Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(37), e20109.

Zhao D, et al. (2026) Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer. *Science advances*, 12(3), eady5324.

Tsui M, et al. (2026) Landscape of Allele-Specific Expression in Prostate Cancer Reveals Recurrent, Stage-Specific Events in AR Signaling and Resistance Pathways. *Molecular cancer research : MCR*, 24(4), 242.

Ji Y, et al. (2026) Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming. *Cancer discovery*, 16(4), 760.

Shah K, et al. (2025) Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(13), 2824.

Kumar R, et al. (2025) CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 39(2), e70342.

San Martin R, et al. (2025) Amorphous calcium phosphate-coated surfaces as a model for bone microenvironment in prostate cancer. *Heliyon*, 11(3), e41929.

Nepali PR, et al. (2025) Effect of TGF-?? mediated phenotypic changes on prostate cancer cell anoikis response. *Oncogene*, 44(50), 4835.

Wierbi??owicz K, et al. (2025) Parp7 generates an ADP-ribosyl degron that controls negative feedback of androgen signaling. *The EMBO journal*, 44(17), 4720.

Alaimo A, et al. (2025) TRPM8 levels determine tumor vulnerability to channel agonists. *Molecular oncology*.

Zhu S, et al. (2025) Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer. *Molecular cell*, 85(14), 2673.

Liu X, et al. (2025) Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival. *bioRxiv : the preprint server for biology*.

Kuzuoglu-Ozturk D, et al. (2025) Small-molecule RNA therapeutics to target prostate cancer. *Cancer cell*, 43(5), 841.